The chemical compositions and targets of the Guanxinjing capsule for the treatment of angina pectoris in coronary heart disease were obtained from TCMSP and GeneCards databases. The STRING database and Cytoscape 3.10.1 software were used to construct the PPI network analysis of the intersecting targets to screen out the core targets. The core targets were subjected to GO and KEGG enrichment analyses, and the core components and core targets were subsequently molecularly docked using AutoDock 4 software. AutoDock 4 software was used to perform molecular docking between the core components and core targets to predict the potential mechanism of action for the treatment of AP in CHD. A total of 127 chemical constituents of the Guanxinjing capsule were screened, corresponding to 366 potential targets that intersected with 1613 targets of AP, and 149 intersecting targets were screened. The analysis revealed that the core targets primarily affect the inflammatory response, apoptosis, and involve various signaling pathways, such as the IL-17, TNF, and PI3K-Akt signaling pathways. The analysis of GO function and KEGG pathway enrichment provides valuable insights into the targets' effects. The molecular docking results indicated high affinities between beta-sitosterol, quercetin, stigmasterol, baicalein, kaempferol, luteolin, tanshinone IIA, and salviolone and the core targets TNF, IL6, PPARG, and TP53. The results showed that the Guanxinjing capsule can exert its therapeutic effect on the angina pectoris of CHD through the relevant signaling pathway.

Tao Wen, Zehui Guo, Yi Wang. Network Pharmacology Prediction and Molecular Docking-Based Strategy for Exploring the Potential Mechanism of the Guanxinjing Capsule in Treating Angina Pectoris. International Journal of Frontiers in Medicine (2025), Vol. 7, Issue 3: 1-16. https://doi.org/10.25236/IJFM.2025.070301.

[1] Y Liu, Geng H-J, Cui X, et al. Clinical comprehensive evaluation of breviscapine injection in treatment of acute cerebral infarction and angina pectoris in coronary heart disease[J]. Chinese traditonal and herbal drugs, 2023, 54(19): 6413-6423.

[2] China-Cardiovascular-Health-And Group. Report on cardiovascular health and diseases in China 2022:an updated summary[J]. Chinese circulation journal, 2023, 38(06): 583-612.

[3] H-J Li, LIU X-Y, Li Z-L, et al. Research progress of therapy of Chinese medicine in treating angina pectoris of coronary heart disease[J]. Journal of Changchun university of Chinese, 2023, 39(11): 1280-1285.

[4] G-H Zhang, Jiang W-J, Zuo W-F, et al. Construction of the regulation network of "component-target-biological process and pathway" in Guanxinjing capsule in the treatment of coronary heart disease[J]. Journal of Shenyang pharmaceutical university, 2020, 37(06): 542-548.

[5] Y-L Dai, Bai H-R. Clinical study on Guanxinjing capsule in treating angina pectoris of Qi deficiency and blood stasis type[J]. Contemporary medicine, 2021, 27(22): 28-30.

[6] X-Y Li. Observation on curative effect of Guanxinjing capsule in treating coronary heart disease and angina pectoris due to qi deficiency and blood stasis[J]. Contemporary medicine, 2018, 24(34): 48-50.

[7] H-J Fan. Observation of the efficacy of Guanxinjing Capsule in the treatment of qi deficiency and blood stasis type coronary heart disease angina pectoris[J]. Chinese journal of integrative medicine on cardio-cerebrovascular disease, 2017, 15(06): 751-754.

[8] H-B Wang, Zhang T-H, Zhang X-B. Clinical efficacy and economic evaluation of Guanxinjing capsule for angina pectoris of coronary heart disease[J]. Chinese journal of drug evaluation, 2017, 34(01): 62-66.

[9] H-J Fan, Li S-R, Kang K-N, et al. Clinical observation of Guanxinjing capsules in treatment of stable exertional angina pectoris[J]. Drugs&Clinic, 2016, 31(07): 1016-1019.

[10] X Li, Wei S, Niu S, et al. Network pharmacology prediction and molecular docking-based strategy to explore the potential mechanism of Huanglian Jiedu Decoction against sepsis[J]. Comput Biol Med, 2022, 144105389. 

[11] H-J Koo, Park H-J, Byeon H-E, et al. Chinese yam extracts containing beta-sitosterol and ethyl linoleate protect against atherosclerosis in apolipoprotein E-deficient mice and inhibit muscular expression of VCAM-1 in vitro[J]. J Food Sci, 2014, 79(4): H719-H729.

[12] Joana-Varlla de Lacerda Alexandre, Viana Yuana-Ivia-Ponte, David Cícera-Edna-Barbosa, et al. Quercetin treatment increases H2O2 removal by restoration of endogenous antioxidant activity and blocks isoproterenol-induced cardiac hypertrophy[J]. Naunyn-Schmiedeberg's Archives of Pharmacology, 2021, 394(2): 217-226.

[13] S Wang, Sun Y, Li C-M, et al. Research progress of stigmasterol[J]. China pharmaceuticals, 2019, 28(23): 96-98.

[14] Q Li, Yu Z, Xiao D, et al. Baicalein inhibits mitochondrial apoptosis induced by oxidative stress in cardiomyocytes by stabilizing MARCH5 expression[J]. J Cell Mol Med, 2020, 24(2): 2040-2051.

[15] Y Zhang, Liu S, Ma J-L, et al. Apocynum venetum leaf extract alleviated doxorubicin-induced cardiotoxicity through the AKT/Bcl-2 signaling pathway[J]. Phytomedicine, 2022, 94153815.

[16] I Andreadou, Iliodromitis E-K, Lazou A, et al. Effect of hypercholesterolaemia on myocardial function, ischaemia-reperfusion injury and cardioprotection by preconditioning, postconditioning and remote conditioning[J]. Br J Pharmacol, 2017, 174(12): 1555-1569.

[17] L Zhao, Zhou Z, Zhu C, et al. Luteolin alleviates myocardial ischemia reperfusion injury in rats via Siti1/NLRP3/NF-kappaB pathway[J]. Int Immunopharmacol, 2020, 85106680.

[18] X Ma, Zhang L, Gao F, et al. Salvia miltiorrhiza and Tanshinone IIA reduce endothelial inflammation and atherosclerotic plaque formation through inhibiting COX-2[J]. Biomed Pharmacother, 2023, 167115501.

[19] Y Yang, Cao Y, Chen L, et al. Cryptotanshinone suppresses cell proliferation and glucose metabolism via STAT3/SIRT3 signaling pathway in ovarian cancer cells[J]. Cancer Med, 2018, 7(9): 4610-4618.

[20] P-M Ridker, Rane M. Interleukin-6 Signaling and Anti-Interleukin-6 Therapeutics in Cardiovascular Disease[J]. Circ Res, 2021, 128(11): 1728-1746.

[21] M Jia, Li Q, Guo J, et al. Deletion of BACH1 Attenuates Atherosclerosis by Reducing Endothelial Inflammation[J]. Circ Res, 2022, 130(7): 1038-1055.

[22] Y Fan, Liu J, Miao J, et al. Anti-inflammatory activity of the Tongmai Yangxin pill in the treatment of coronary heart disease is associated with estrogen receptor and NF-kappaB signaling pathway[J]. J Ethnopharmacol, 2021, 276114106.

[23] R Dorajoo, Ihsan M-O, Liu W, et al. Vascular smooth muscle cells in low SYNTAX scores coronary artery disease exhibit proinflammatory transcripts and proteins correlated with IL1B activation[J]. Atherosclerosis, 2023, 36515-24.

[24] J-J Liu, Jing L-X, Wang J. Correlation of plasma heme oxygenase-1 and matrix metalloproteinase-9 with coronary artery disease[J]. Journal of army medical university, 2018, 40(13): 1247-1250.

[25] N Rani, Arya D-S. Chrysin rescues rat myocardium from ischemia-reperfusion injury via PPAR-gamma/Nrf2 activation[J]. Eur J Pharmacol, 2020, 883173389.

[26] L Ma, Dai X, Wu C, et al. Tanyu Tongzhi Formula Delays Atherosclerotic Plaque Progression by Promoting Alternative Macrophage Activation via PPARgamma and AKT/ERK Signal Pathway in ApoE Knock-Out Mice[J]. Front Pharmacol, 2021, 12734589.

[27] Q Chen, Thompson J, Hu Y, et al. Cardiomyocyte specific deletion of p53 decreases cell injury during ischemia-reperfusion: Role of Mitochondria[J]. Free Radic Biol Med, 2020, 158, 162-170.

[28] Y Cai, Ying F, Liu H, et al. Deletion of Rap1 protects against myocardial ischemia/reperfusion injury through suppressing cell apoptosis via activation of STAT3 signaling[J]. FASEB J, 2020, 34(3): 4482-4496.

[29] R Blanco-Dominguez, de la Fuente H, Rodriguez C, et al. CD69 expression on regulatory T cells protects from immune damage after myocardial infarction[J]. J Clin Invest, 2022, 132(21).

[30] Y-F Song, Zhao L, Wang B-C, et al. The circular RNA TLK1 exacerbates myocardial ischemia/reperfusion injury via targeting miR-214/RIPK1 through TNF signaling pathway[J]. Free Radic Biol Med, 2020, 15569-80.

[31] X Chen, Wang R, Chen W, et al. Decoy receptor-3 regulates inflammation and apoptosis via PI3K/AKT signaling pathway in coronary heart disease[J]. Exp Ther Med, 2019, 17(4): 2614-2622.